Enquirer Consulting Group

Resolian Buyer Map

Rob Stachlewitz | Resolian | October 2026

As of 28 Oct 2026

Resolian sells bioanalytical, biomarker and analytical sciences work across every phase of drug development, so its buyers sit inside the organizations that develop and make medicines.

This page maps those organizations by type, with a banded public count where a clean one exists, and the roles that usually sign off on outsourced lab work at each.

Where Resolian's buyers sit

Counted for United States organizations only. Resolian also serves sponsors in the UK, Europe, Australia and China, which these counts leave out.

GroupOrganizations in the USUnder 20 staff20 to 99100 to 499500 or more
Pharmaceutical drug manufacturersabout 1,200about 660about 220about 170about 130
Biological product manufacturers, including antibodies and other biologicsabout 290about 150about 51about 32about 61
Biotechnology research and development companiesabout 4,900about 4,000about 600about 240about 130
Surgical and medical device manufacturersabout 2,700about 1,800about 480about 220about 190
Cell and gene therapy developersno clean public count

US firm counts by industry code, banded deliberately.

Who signs off on bioanalysis and biomarker work

At a drug developer, outsourced bioanalysis is usually chosen by the scientist who owns that data in the regulatory filing, then approved by an outsourcing or procurement lead once the scope is set.

Organization typeUsually signs offAlso in the room
Large pharmaceutical companiesHead of Bioanalysis or Business Lead, Clinical BioanalysisClinical outsourcing and procurement
Mid size and emerging biotechDirector of DMPK and Clinical PharmacologyChief Scientific Officer or VP Development
Biologics and drug conjugate developersDirector of Bioanalytical and Biomarker OperationsHead of Immunogenicity or Translational Science
Cell and gene therapy developersHead of Translational Science or BiomarkersVP Clinical Development

Who signs off on analytical sciences and CMC work

Resolian's analytical sciences side tests the drug product and its materials: impurities, nitrosamines, extractables and leachables, characterization and batch release. Here the buyer sits in CMC, quality or manufacturing rather than in the clinical team.

Organization typeUsually signs offAlso in the room
Pharmaceutical manufacturersHead of CMC or Director of Analytical DevelopmentQuality Control and Quality Assurance leads
Biologics manufacturersDirector of Analytical DevelopmentHead of Process Development
Medical device manufacturersDirector of Regulatory AffairsBiocompatibility or toxicology lead
Early stage drug developersVP CMC or Head of Pharmaceutical DevelopmentChief Executive or Chief Scientific Officer

How the decision usually runs

Lab partners are usually picked program by program, at the point a molecule moves toward the clinic or into a new phase. Method transfer, regulatory track record and one project lead across countries tend to decide it, which is the case Resolian's own site makes.

Ten people to start with

The people who usually sign at the groups above, one a company. Work emails and phone numbers checked on Oct 28, 2026.

NameRoleCompanyWhereEmailPhone
Rory M DoyleDirector of BioanalysisLarimar Therapeutics Inc.Philadelphiardoyle@larimartx.com+1 202 297 2894
Mahmoud ElAzzounyDirector of BioanalysisExelixisSanta Clara, CAmelazzouny@exelixis.com+1 734 223 1599
John T BarrHead of DMPKCalico Life SciencesSan Francisco Bayjohnbarr@calicolabs.com
Mette OttosenDirector of Analytical DevelopmentFUJIFILM BiotechnologiesDenmarkmette.ottosen@fujifilm.com
Eran BenjaminDirector of Analytical DevelopmentAerogen PharmaSan Mateo, CAebenjamin@aerogenpharma.com+1 424 731 0168
Damian HoudeDirector of Analytical DevelopmentInvivydCambridge, MAdhoude@invivyd.com+1 617 750 1539
Lily MedinaDirector of Regulatory AffairsVentyx BiosciencesSan Diego, CAlmedina@ventyxbio.com+1 619 988 5459
Kelly HunterDirector of Regulatory AffairsOrthocell LtdPerth, Australiakelly.hunter@orthocell.com
Nazma ChaudhryDirector of Regulatory AffairsZOLL Medical CorporationPleasanton, CAnazma.chaudhry@zoll.com+1 707 578 0450
Richard HinesDirector of Regulatory AffairsImpediMedEscondido, CArhines@impedimed.com+1 949 395 8795

Where to start

Programs that cross borders

The site leads on assay transfer across Australia, the US, the UK and China under harmonized quality systems. Sponsors whose programs will run studies in more than one of those countries are the first conversation, through the bioanalysis and DMPK leads above.

Complex modalities

The site shows depth in antibody drug conjugates, oligonucleotides, immunogenicity and cell and gene therapy. Developers of those molecules face harder bioanalysis than small molecule programs, so their translational and bioanalytical leads are a group to work by modality rather than by company size.

Emerging biotech

Resolian publishes guidance for biopharma startups choosing a bioanalytical partner. Venture backed biotechs nearing first in human studies often have no bioanalysis team of their own, so a founder, Chief Scientific Officer or head of development signs directly and the cycle is shorter.

Built from public federal registries and the company's own website, counts banded deliberately.

If a walk-through is useful, pick a time at cal.com/ecg.

Prepared by Dan Reeves, dan@enquirerconsulting.com.